S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Trial ID or NCT#

NCT03091660

Status

not recruiting iconNOT RECRUITING

Purpose

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.

Official Title

S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Eila C. Skinner
Eila C. Skinner
Urologic oncologist, Urologist, Urologic surgeon
Thomas A. Stamey Research Professor of Urology
Harcharan Gill
Harcharan Gill
Urologic oncologist, Urologist, Genitourinary specialist, Urologic surgeon
Kathryn Simmons Stamey Professor, Emeritus
Benjamin I. Chung
Benjamin I. Chung
Urologic oncologist, Urologic specialist, Urologist, Genitourinary specialist, Urologic surgeon
Associate Professor of Urology

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov